JP2020521786A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020521786A5 JP2020521786A5 JP2019565949A JP2019565949A JP2020521786A5 JP 2020521786 A5 JP2020521786 A5 JP 2020521786A5 JP 2019565949 A JP2019565949 A JP 2019565949A JP 2019565949 A JP2019565949 A JP 2019565949A JP 2020521786 A5 JP2020521786 A5 JP 2020521786A5
- Authority
- JP
- Japan
- Prior art keywords
- drug according
- cancer
- combination drug
- inhibitor
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940000425 combination drug Drugs 0.000 claims 11
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 7
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 7
- 239000003112 inhibitor Substances 0.000 claims 7
- 229960003301 nivolumab Drugs 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 229960002621 pembrolizumab Drugs 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 230000003463 hyperproliferative effect Effects 0.000 claims 3
- 229950009791 durvalumab Drugs 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 239000002138 L01XE21 - Regorafenib Substances 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000006593 Urologic Neoplasms Diseases 0.000 claims 1
- 229960003852 atezolizumab Drugs 0.000 claims 1
- 229950002916 avelumab Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000024519 eye neoplasm Diseases 0.000 claims 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 201000008106 ocular cancer Diseases 0.000 claims 1
- 210000002990 parathyroid gland Anatomy 0.000 claims 1
- 229960004836 regorafenib Drugs 0.000 claims 1
- ZOPOQLDXFHBOIH-UHFFFAOYSA-N regorafenib hydrate Chemical compound O.C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 ZOPOQLDXFHBOIH-UHFFFAOYSA-N 0.000 claims 1
- 201000011453 reproductive organ cancer Diseases 0.000 claims 1
- 208000015608 reproductive system cancer Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 229940066453 tecentriq Drugs 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022138972A JP7475402B2 (ja) | 2017-06-02 | 2022-09-01 | 癌治療のためのレゴラフェニブとｐｄ－１／ｐｄ－ｌ１（２）阻害剤の併用 |
| JP2024066115A JP2024096905A (ja) | 2017-06-02 | 2024-04-16 | 癌治療のためのレゴラフェニブとｐｄ－１／ｐｄ－ｌ１（２）阻害剤の併用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17174169 | 2017-06-02 | ||
| EP17174169.7 | 2017-06-02 | ||
| PCT/EP2018/063785 WO2018219807A1 (en) | 2017-06-02 | 2018-05-25 | Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022138972A Division JP7475402B2 (ja) | 2017-06-02 | 2022-09-01 | 癌治療のためのレゴラフェニブとｐｄ－１／ｐｄ－ｌ１（２）阻害剤の併用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020521786A JP2020521786A (ja) | 2020-07-27 |
| JP2020521786A5 true JP2020521786A5 (enExample) | 2021-09-16 |
| JP7303122B2 JP7303122B2 (ja) | 2023-07-04 |
Family
ID=58992733
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019565949A Active JP7303122B2 (ja) | 2017-06-02 | 2018-05-25 | 癌治療のためのレゴラフェニブとｐｄ－１／ｐｄ－ｌ１（２）阻害剤の併用 |
| JP2022138972A Active JP7475402B2 (ja) | 2017-06-02 | 2022-09-01 | 癌治療のためのレゴラフェニブとｐｄ－１／ｐｄ－ｌ１（２）阻害剤の併用 |
| JP2024066115A Pending JP2024096905A (ja) | 2017-06-02 | 2024-04-16 | 癌治療のためのレゴラフェニブとｐｄ－１／ｐｄ－ｌ１（２）阻害剤の併用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022138972A Active JP7475402B2 (ja) | 2017-06-02 | 2022-09-01 | 癌治療のためのレゴラフェニブとｐｄ－１／ｐｄ－ｌ１（２）阻害剤の併用 |
| JP2024066115A Pending JP2024096905A (ja) | 2017-06-02 | 2024-04-16 | 癌治療のためのレゴラフェニブとｐｄ－１／ｐｄ－ｌ１（２）阻害剤の併用 |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US11951166B2 (enExample) |
| EP (2) | EP4342542A3 (enExample) |
| JP (3) | JP7303122B2 (enExample) |
| KR (2) | KR102673422B1 (enExample) |
| CN (3) | CN117582495A (enExample) |
| AU (2) | AU2018276273B2 (enExample) |
| BR (1) | BR112019025478A8 (enExample) |
| CA (2) | CA3244313A1 (enExample) |
| DK (1) | DK3630112T3 (enExample) |
| ES (1) | ES2978337T3 (enExample) |
| FI (1) | FI3630112T3 (enExample) |
| HR (1) | HRP20240551T1 (enExample) |
| HU (1) | HUE066487T2 (enExample) |
| IL (2) | IL317015A (enExample) |
| LT (1) | LT3630112T (enExample) |
| MX (1) | MX2023001721A (enExample) |
| PE (2) | PE20200859A1 (enExample) |
| PL (1) | PL3630112T3 (enExample) |
| PT (1) | PT3630112T (enExample) |
| RS (1) | RS65488B9 (enExample) |
| SI (1) | SI3630112T1 (enExample) |
| WO (1) | WO2018219807A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE066487T2 (hu) * | 2017-06-02 | 2024-08-28 | Bayer Healthcare Llc | Regorafenib és nivolumab kombinációja rák kezelésére |
| CN111001004A (zh) * | 2019-10-08 | 2020-04-14 | 广州医科大学附属第二医院 | 一种治疗肝癌的药物组合及其应用 |
| WO2025117638A1 (en) * | 2023-12-01 | 2025-06-05 | Yale University | Compositions and methods for treating cancer |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ544920A (en) | 2003-07-23 | 2009-11-27 | Bayer Healthcare Llc | 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions |
| WO2007054303A2 (en) | 2005-11-10 | 2007-05-18 | Bayer Healthcare Ag | Diaryl urea for treating diabetic neuropathy |
| AR062927A1 (es) | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
| AR081060A1 (es) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
| AR092439A1 (es) | 2012-09-06 | 2015-04-22 | Bayer Healthcare Llc | Composicion farmaceutica recubierta que contiene regorafenib |
| RS57875B1 (sr) | 2012-09-25 | 2018-12-31 | Bayer Pharma AG | Kombinacija regorafeniba i acetilsalicilne kiseline za lečenje kolorektalnog kancera |
| JP5653489B1 (ja) | 2013-07-24 | 2015-01-14 | 三菱エンジニアリングプラスチックス株式会社 | 薄肉光学部材用ポリカーボネート樹脂ペレット及びその製造方法 |
| EP3498734B1 (en) | 2014-02-04 | 2021-09-01 | Pfizer Inc. | Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer |
| US20170165364A1 (en) | 2014-02-21 | 2017-06-15 | Idac Theranostics, Inc. | Therapeutic agent for solid cancer |
| CA2954508A1 (en) | 2014-07-15 | 2016-01-21 | Genentech, Inc. | Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| CN107072984B (zh) | 2014-07-15 | 2021-10-01 | 约翰·霍普金斯大学 | 源自骨髓的抑制细胞的抑制和免疫检查点阻断 |
| US10392444B2 (en) * | 2014-08-08 | 2019-08-27 | Oncoquest, Inc. | Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer |
| KR20170042778A (ko) * | 2014-08-19 | 2017-04-19 | 고꾸리츠 다이가꾸 호우징 오까야마 다이가꾸 | 면역 세포의 기능 증강 방법 및 면역 세포의 다기능성 평가 방법 |
| US20170209574A1 (en) | 2014-10-03 | 2017-07-27 | Novartis Ag | Combination therapies |
| KR20170080697A (ko) | 2014-11-13 | 2017-07-10 | 더 존스 홉킨스 유니버시티 | 관문 차단 및 미소부수체 불안정성 |
| WO2016173959A1 (en) * | 2015-04-28 | 2016-11-03 | Bayer Pharma Aktiengesellschaft | Regorafenib for treating colorectal cancer |
| US20190022092A1 (en) | 2015-09-15 | 2019-01-24 | Acerta Pharma B.V. | Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist |
| EP3463456A1 (en) | 2016-06-03 | 2019-04-10 | ImClone LLC | Combination of ramucirumab and pembrolizumab for the treatment of certain cancers |
| US10251888B2 (en) | 2016-06-13 | 2019-04-09 | Chemocentryx, Inc. | Method of treating pancreatic cancer |
| HUE066487T2 (hu) * | 2017-06-02 | 2024-08-28 | Bayer Healthcare Llc | Regorafenib és nivolumab kombinációja rák kezelésére |
| KR102692379B1 (ko) * | 2017-06-05 | 2024-08-05 | 얀센 바이오테크 인코포레이티드 | Pd-1과 특이적으로 결합하는 항체 및 사용 방법 |
-
2018
- 2018-05-25 HU HUE18725258A patent/HUE066487T2/hu unknown
- 2018-05-25 CN CN202311446796.9A patent/CN117582495A/zh active Pending
- 2018-05-25 EP EP24150061.0A patent/EP4342542A3/en active Pending
- 2018-05-25 PT PT187252580T patent/PT3630112T/pt unknown
- 2018-05-25 DK DK18725258.0T patent/DK3630112T3/da active
- 2018-05-25 PL PL18725258.0T patent/PL3630112T3/pl unknown
- 2018-05-25 JP JP2019565949A patent/JP7303122B2/ja active Active
- 2018-05-25 CA CA3244313A patent/CA3244313A1/en active Pending
- 2018-05-25 SI SI201831091T patent/SI3630112T1/sl unknown
- 2018-05-25 CN CN201880036504.5A patent/CN110662540B/zh active Active
- 2018-05-25 BR BR112019025478A patent/BR112019025478A8/pt not_active Application Discontinuation
- 2018-05-25 IL IL317015A patent/IL317015A/en unknown
- 2018-05-25 LT LTEPPCT/EP2018/063785T patent/LT3630112T/lt unknown
- 2018-05-25 US US16/617,642 patent/US11951166B2/en active Active
- 2018-05-25 RS RS20240481A patent/RS65488B9/sr unknown
- 2018-05-25 CN CN202410088226.5A patent/CN117899212A/zh active Pending
- 2018-05-25 ES ES18725258T patent/ES2978337T3/es active Active
- 2018-05-25 IL IL270948A patent/IL270948B2/en unknown
- 2018-05-25 AU AU2018276273A patent/AU2018276273B2/en active Active
- 2018-05-25 WO PCT/EP2018/063785 patent/WO2018219807A1/en not_active Ceased
- 2018-05-25 HR HRP20240551TT patent/HRP20240551T1/hr unknown
- 2018-05-25 KR KR1020197038281A patent/KR102673422B1/ko active Active
- 2018-05-25 EP EP18725258.0A patent/EP3630112B9/en active Active
- 2018-05-25 FI FIEP18725258.0T patent/FI3630112T3/fi active
- 2018-05-25 PE PE2019002499A patent/PE20200859A1/es unknown
- 2018-05-25 KR KR1020247017968A patent/KR102843438B1/ko active Active
- 2018-05-25 PE PE2024001939A patent/PE20242220A1/es unknown
- 2018-05-25 CA CA3065125A patent/CA3065125C/en active Active
-
2019
- 2019-12-02 MX MX2023001721A patent/MX2023001721A/es unknown
- 2019-12-31 US US16/731,409 patent/US20200155674A1/en not_active Abandoned
- 2019-12-31 US US16/731,412 patent/US11517622B2/en active Active
-
2022
- 2022-01-14 US US17/576,522 patent/US20220133888A1/en active Pending
- 2022-09-01 JP JP2022138972A patent/JP7475402B2/ja active Active
-
2023
- 2023-12-12 AU AU2023282197A patent/AU2023282197B2/en active Active
-
2024
- 2024-04-16 JP JP2024066115A patent/JP2024096905A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015529234A5 (enExample) | ||
| JP2022017296A (ja) | Ｈｄａｃ阻害剤とｐｄ－１阻害剤との組み合わせ療法 | |
| JP2015511609A5 (enExample) | ||
| JP2015536964A5 (enExample) | ||
| JP2022169780A5 (enExample) | ||
| KR20170122220A (ko) | 브루톤 타이로신 키나제 저해제의 약제학적 제제 | |
| JP2020515578A5 (enExample) | ||
| JP2016528162A5 (enExample) | ||
| JP2019508440A5 (enExample) | ||
| KR20190022520A (ko) | Hdac 억제제 및 pd-l1 억제제의 병용 요법 | |
| JP2019506403A5 (enExample) | ||
| JP2014132009A5 (enExample) | ||
| JP2015534578A5 (enExample) | ||
| JP2016536286A5 (enExample) | ||
| JP2016528246A5 (enExample) | ||
| JP2018508516A5 (enExample) | ||
| JP2015536986A5 (enExample) | ||
| JP2017526700A5 (enExample) | ||
| JP2016515628A5 (enExample) | ||
| JP2017530983A5 (enExample) | ||
| JP2015524472A5 (enExample) | ||
| HK1259434A1 (zh) | 包含btk抑制剂的配制品/组合物 | |
| JP2019532047A5 (enExample) | ||
| JP2019530706A5 (enExample) | ||
| JP2020521786A5 (enExample) |